PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Sivelestat Lowers Sepsis-ARDS Mortality in Small, East Asian Studies

sivelestatneutrophil elastase inhibitorsepsisacute respiratory distress syndromeARDSmeta-analysiscritical caremortalityadjunctive therapyulinastatinphenotype enrichment Infectious Disease / Antimicrobials

Background Information

Sivelestat may lower mortality in sepsis-induced ARDS.

Sepsis-induced acute respiratory distress syndrome (ARDS) has high mortality, and therapies like sivelestat could improve outcomes. Sivelestat reduced mortality in sepsis-induced ARDS (OR=0.55, 95% CI 0.36-0.84) in a meta-analysis of 10 studies. While sivelestat shows promise in reducing mortality, evidence is not yet sufficient to guide phenotype-based prescribing. Reliance on co-intervention discrepancies limits applicability. Sivelestat may reduce mortality in sepsis-induced ARDS, but evidence lacks clarity for guided usage.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Haibier A, Ma J, Wang Y, Wu T

Citation: Haibier A, Ma J, Wang Y, et al. Efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome: an updated meta-analysis based on disease severity and treatment strategy subgroups. Frontiers in medicine. 2026;13:1986111. doi:10.3389/fmed.2026.1986111

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.